赛隆药业(002898) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥62,681,719.81, representing a decrease of 8.62% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥5,457,662.55, a decline of 508.30% year-over-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥5,431,143.09, down 390.06% from the previous year[2]. - Total operating revenue for Q3 2024 was CNY 218,744,136.56, a decrease of 2.8% compared to CNY 225,377,845.96 in the same period last year[12]. - Net profit for Q3 2024 was CNY 728,862.11, down from CNY 6,633,783.59 in the previous year, indicating a significant decline[13]. - Basic and diluted earnings per share for Q3 2024 were both CNY -0.0210, compared to CNY 0.0246 in the previous year[14]. Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥31,732,542.11, a significant decline of 1,220.30% year-over-year[2]. - Cash flow from operating activities was CNY 136,585,109.63, compared to CNY 220,459,446.66 in the same period last year, representing a decrease of 38.0%[15]. - The net cash flow from operating activities was -31,732,542.11, a significant decline compared to 2,832,502.63 in the previous quarter[16]. - Cash outflow from operating activities totaled 168,317,651.74, down from 217,626,944.03 in the previous quarter[16]. - The ending balance of cash and cash equivalents was 58,452,728.32, compared to 14,875,363.10 in the previous quarter[16]. Assets and Liabilities - The total assets at the end of Q3 2024 amounted to ¥841,078,264.26, an increase of 3.35% from the end of the previous year[2]. - The total liabilities increased to CNY 312,409,560.75 from CNY 277,961,889.44, marking an increase of 12.4%[12]. - Non-current liabilities rose to CNY 63,375,548.47 from CNY 50,951,685.42, an increase of 24.4%[12]. - The total equity attributable to shareholders of the parent company decreased to CNY 528,668,703.51 from CNY 535,881,684.91, a decline of 1.9%[12]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 18,395[7]. - The largest shareholder, Cai Nanguai, holds 51.15% of the shares, totaling 90,016,937 shares[7]. Operational Metrics - The company reported a significant increase in operating income from non-main business activities, rising 4980.19% to ¥916,659.85[6]. - The company reported a significant increase in accounts receivable by 187.13% to ¥81,517,253.58 due to increased credit sales during the period[5]. - The company experienced a 366.46% increase in financial assets due to the purchase of wealth management products[5]. - The company has ongoing investments in new product development, with development expenditures rising from ¥45,736,772.18 to ¥50,153,934.08, an increase of about 9%[11]. Inventory and Borrowings - Short-term borrowings increased from ¥90,047,819.38 to ¥118,270,858.89, a rise of approximately 31%[11]. - The company reported a significant increase in accounts receivable financing from ¥11,202,134.68 to ¥8,629,349.96, indicating a shift in financing strategy[11]. - The company reported a significant increase in long-term borrowings to CNY 32,850,000.00 from CNY 25,080,000.00, an increase of 30.8%[12]. Other Financial Metrics - The company's cash and cash equivalents decreased from ¥87,118,672.26 to ¥58,454,477.12, a decline of approximately 33%[10]. - Total current assets rose from ¥256,302,322.01 to ¥274,931,746.20, an increase of approximately 7%[11]. - Total operating costs decreased to CNY 220,696,045.74 from CNY 230,669,924.19, reflecting a reduction of 4.3%[12]. - The total cash outflow for operating activities related to employee payments was 47,969,808.39, slightly down from 49,499,436.21 in the previous quarter[16]. - The total cash outflow for taxes paid was 18,253,976.51, a decrease from 26,343,588.30 in the previous quarter[16]. Audit Status - The company has not undergone an audit for the third quarter report[17].